Systemic Akt1 deletion inhibited lung metastases whereas systemic Akt2 deletion enhanced mammary tumorigenesis and metastasis at least in HER2-enriched and luminal B mouse models of breast cancer [103]. The gene discussed is AKT1; the disease is breast carcinoma.